Compare MGM Resorts International (MGM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Regeneron Pharmaceuticals Inc — how do they compare? MGM Resorts International trades at $43.5 (market cap $10.91B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.6× MGM Resorts International's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.47%). Which is the better fit depends on your goals.
| MGM | REGN | |
|---|---|---|
Market Cap | $10.91B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $812.27 |
52-Week Low | $30.72 | $555.51 |
Enterprise Value | $38.21B | $77.90B |
Dividend Yield | 0.03% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $44.47, down 0.51% on the day, with a bearish technical signal and neutral oscillators. The company reported record Q2 2026 revenue but missed earnings estimates, with net income margin at 2.4% and ROE at 15.44%. Recent news includes a potential acquisition investigation and BetMGM's expansion in Canada, while cash flow trends show improving net cash flow projections for 2026.
Outlook is mixed: analyst consensus leans neutral with a $51.14 price target, but risks include regulatory scrutiny and competitive pressures. The stock offers value with a P/S of 0.66, but investors should weigh earnings volatility and debt levels against growth in digital and Las Vegas operations.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
